Citigroup Maintains Buy on Bio-Techne, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly maintains a Buy rating on Bio-Techne (NASDAQ:TECH) but lowers the price target from $100 to $80.
November 01, 2023 | 8:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup maintains a Buy rating on Bio-Techne but lowers the price target from $100 to $80.
While the Buy rating is maintained, the lowered price target could potentially impact investor sentiment and the stock's short-term performance. However, the overall impact is neutral as the Buy rating indicates that Citigroup still sees potential in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100